News & Events about Erasca Inc.
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41st annual J...
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Bihua Chen bought 307,692 shares of the firms stock in a transaction that occurred on Tuesday, December 13th. The stock was purchased at an average cost of $6.50 per share, with a total value of $1,999,998.00. Following the completion of the transaction...
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therapies and ...
Market News Video
1month ago
In trading on Monday, shares of Erasca Inc (ERAS) touched a new 52-week low of 4.34/share. Thats a 11.66 share price drop, or -72.88% decline from the 52-week high of 16.00 set back on 12/31/2021...
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...